|
 |
PhosLoThis page contains recent news articles, when available, and an overview of PhosLo but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The operating margin development was negatively influenced by increased prices for pharmaceuticals, the impact of the launch of a generic version of PhosLo® ... Reuters Nabi Biopharmaceuticals Reports Operating Results (10-Q) - Nov 5, 2009 In November 2006, we sold our PhosLo (calcium acetate) product and the product's related assets to a US subsidiary of Fresenius Medical Care, or Fresenius. ... GuruFocus.com Nabi Biopharmaceuticals Announces Third Quarter 2009 Financial Results - Nov 5, 2009 ...collect further milestone and royalty payments under the PhosLo Agreement; obtain regulatory approval for our products in the US or other markets; ... Reuters Nabi Biopharmaceuticals Completes Sale of PentaStaph(TM) to GlaxoSmithKline PLC - Nov 4, 2009 ...collect further milestone and royalty payments under the PhosLo Agreement; obtain regulatory approval for our products in the US or other markets; ... Reuters Sandoz introduces two new generic drugs - Oct 20, 2009 Johnson's epilepsy drug Topamax Sprinkle, and calcium acetate capsules, an authorized generic of Fresenius Medical Care's kidney failure drug PhosLo. ... Trading Markets (press release) Nabi Biopharmaceuticals Participates in NicVAX(R) Phase IIb Study - Oct 28, 2009 ...collect further milestone and royalty payments under the PhosLo Agreement; obtain regulatory approval for our products in the US or other markets; ... Reuters FMC hebt Jahresprognose leicht an (zwei) - Nov 2, 2009 Gegenläufig hätten sich höhere Preise für Dialysemedikamente, die Einführung eines Generikums des Phosphatbinders Phoslo auf dem US-Markt durch einen ... Märkische Allgemeine AUSBLICK/Fresenius Gruppe wächst in allen Sparten in 3Q - Oct 30, 2009 Im zweiten Halbjahr sollte sich die Marge unter anderem dank einer verstärkten internationalen Vermarktung von Phoslo nach Einschätzung von MM Warburg aber ... Märkische Allgemeine Fresenius Medical Care sube el beneficio un 7 por ciento hasta septiembre - Nov 3, 2009 ...la versión genérica de PhosLo, que es acetato de calcio y se utiliza para tratar los niveles altos de fosfato en pacientes con un fallo renal crónico. ... Invertia (Colombia) FMC übertrifft mit 3Q Erwartungen und hebt Ergebnisprognose an - Nov 3, 2009 Belastet hätten allerdings höhere Preise für Dialysemedikamente, die Einführung eines Generikums des Phosphatbinders Phoslo auf dem US-Markt durch einen ... Märkische Allgemeine Fresenius Medical Care kaufen - Nov 4, 2009 ...belastender Effekte wie generisches PhosLo und negativen Währungseffekten - und sei durch die Zunahme bei der durchschnittlichen Vergütung je Behandlung ... AktienCheck Fresenius: 1.−3. Quartal 2009: Starkes organisches Wachstum erreicht ... - Nov 4, 2009 ...höhere Preise von Dialysemedikamenten sowie die Einführung eines Generikums des Phosphatbinders PhosLo® durch einen Wettbewerber in den USA. ... Business-News (Pressemitteilung) Nabi to sell off PhosLo drug - Oct 12, 2006 For $150 million in up-front cash, milestone payments and royalties on sales of a new product formulation under development, Nabi Biopharmaceuticals has ... Bizjournals.com FMC seeks FDA nod of new drug use for PhosLo - Jan 23, 2007 ...(FDA) to use its phosphate binder, PhosLo, for Stage 4 chronic kidney disease, the German dialysis care group said on Tuesday. ... Reuters Nabi will sell PhosLo for up to $150 million - Oct 13, 2006 Nabi Biopharmaceuticals (NABI), a Boca Raton biotech firm, announced this morning it has agreed to sell PhosLo and the product's related assets to an ... $2.95 - Miami Herald - NewsBank Nabi Biopharmaceuticals Initiates PhosLo(R) Epick Study in Chronic … - May 10, 2005 BOCA RATON, Fla., May 10 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced the initiation of its PhosLo(R) (calcium acetate) EPICK study in ... RedOrbit Nabi Biopharmaceuticals Announces Receipt of $2.5 Million Milest - Jun 3, 2008 ..."I am very pleased that we have achieved yet another milestone toward realizing the significant remaining value of our PhosLo revenue stream," said Dr. ... Bloomberg Nabi Finds Option Errors - Nov 15, 2006 Nabi had been accounting for its PhosLo business as a discontinued ... PhosLo controls the level of phosphorous in patients with end-stage kidney disease. ... TheStreet.com - TheStreet.com (subscription) Nabi reaches settlement in patent dispute - Apr 3, 2008 The case regarding PhosLo GelCaps was dismissed from the US District Court ... After Nabi sold PhosLo to Fresenius, the local company was still subject to ... Bizjournals.com … Medical Care Announces Positive Results From PhosLo CARE-2 Study - Nov 21, 2006 Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) (FWB:FME) today announced positive results from the PhosLo (calcium acetate) CARE-2 (Calcium Acetate Renagel ... RedOrbit Nabi Biopharmaceuticals' New PhosLo Share Program(TM) Expands … - Aug 3, 2005 BOCA RATON, Fla., Aug. 3 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced it has launched the PhosLo Share Program(TM), an initiative that ... $4.95 - PR Newswire - ECNext Nabi's Sales Decline | Pharmaceuticals | Financial Articles &... - Oct 25, 2006 PhosLo, a drug that prevents the build-up of excessive phosphorous levels in the blood, contributed $6.8 million in sales during the third quarter vs. ... TheStreet.com - TheStreet.com (subscription) … 2007 - 72 FR 43643 Determination That PHOSLO (Calcium Acetate) 667... - Aug 6, 2007 PHOSLO (calcium acetate) 667-mg tablet is indicated for the control of ... The agency has determined that Fresenius's PHOSLO (calcium acetate) 667-mg tablet ... Pay-Per-View - Federal Register 2007 - Loislaw … Release: Nabi Biopharmaceuticals' New PhosLo Share Program(TM) … - Aug 3, 2005 Nabi Biopharmaceuticals' New PhosLo Share Program(TM) Expands Access to Broader Population of End-Stage Renal (Kidney) Disease Patients On Hemodialysis. Pay-Per-View - PR Newswire - HighBeam Research … Biopharmaceuticals (NABI) Announces Positive Results from PhosLo … - Oct 16, 2006 The EPICK study was designed to demonstrate that PhosLo is effective and safe in controlling hyperphosphatemia in Stage 4 CKD patients without causing very ... StreetInsider.com - StreetInsider.com (subscription) BOCA-BASED NABI PUTS DOWN ROOTS IN IRELAND - Apr 26, 2005 Nabi also has filed for European approval of PhosLo, a drug that controls elevated phosphorus levels in ... PhosLo already is marketed in the United States. Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver RBT Roundtable: The Renal Diet - Jun 30, 2008 The physician that developed PhosLo years ago did so to treat his young daughter with ... PhosLo continues to provide patients with good phosphorus control, ... Renal Business Today … : Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius … - Nov 14, 2006 Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Nabi Biopharmaceuticals Updates European Commercialization Strategy. - Dec 19, 2005 PhosLo is a prescription phosphate binder indicated for the control of ... Future clinical infrastructure and marketing support for PhosLo and HEBIG can be ... Free with registration - PR Newswire - AccessMyLibrary.com Nabi Biopharmaceuticals Announces Creation of Pharmaceuticals … - Jul 20, 2007 ...development programs, as well as for the continuing milestone-related development obligations following the sale of PhosLo(R) (calcium acetate). ... Free with registration - PR Newswire - AccessMyLibrary.com … Announces Positive Results From PhosLo(R) EPICK Study. - PR … - Oct 16, 2006 Nabi Biopharmaceuticals Announces Positive Results From PhosLo(R) EPICK Study. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Nabi Biopharmaceuticals Reports Second Quarter 2005 Results. - Jul 19, 2005 Management also noted that total prescriptions for PhosLo(R) (calcium acetate) ... After considering all of these factors, patient utilization of PhosLo ... $4.95 - PR Newswire - ECNext Nabi logs larger loss in Q1 - Apr 27, 2006 The company credited much of its most recent revenue gain to PhosLo, a drug for patients with kidney disease. Nabi said the medication saw both an increase ... Bizjournals.com … Files Lawsuit for Infringement of its PhosLo(R) Gelcap Patent. -... - Sep 27, 2005 Nabi Biopharmaceuticals Files Lawsuit for Infringement of its PhosLo(R) Gelcap Patent. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Nabi Biopharmaceuticals Reports Second Quarter 2006 Results. - Jul 26, 2006 The increase was driven by improved pricing and strong patient demand for PhosLo(R) (calcium acetate). Net loss reported for the quarter ended July 1, ... Free with registration - PR Newswire - AccessMyLibrary.com … Files Lawsuit for Infringement of its PhosLo(R) Gelcap Patent. - Sep 27, 2005 PhosLo is a prescription phosphate binder currently indicated for the control of hyperphosphatemia in patients with end-stage renal (kidney) disease (ESRD). ... $4.95 - PR Newswire - ECNext Q1 2006 Nabi Biopharmaceuticals Earnings Conference Call - Final. - Apr 26, 2006 In the first quarter of 2006, PhosLo revenues increased $8 million. ... Our license submission for PhosLo in Europe has now advanced in six important ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Nabi sees larger Q3 loss - Oct 20, 2005 PhosLo were $8.1 million, down from $9.2 million for the same period the year ... For the year, Nabi projected PhosLo sales in the range of $26 million to ... South Florida Business Journal Fresenius Medical Care Announces: Continued Positive Data from CARE … - Nov 7, 2007 These findings will provide additional data on the safety of PhosLo as the Company works ... Patients treated with PhosLo and sevelamer achieved comparable ... Genetic Engineering News - Genetic Engineering News (press release) Nabi Biopharmaceuticals Appoints Vice President of Sales and Marketing... - Sep 8, 2005 We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol ... RedOrbit Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical... - Nov 14, 2006 BOCA RATON, Fla., Nov. 14 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals announced today that it has completed the previously announced sale of PhosLo(R) ... $4.95 - PR Newswire - ECNext Nabi Biopharmaceuticals Reports Year-End and Fourth Quarter 2004 … - Feb 15, 2005 In 2005, he will direct efforts toward the launches of StaphVAX, PhosLo, and HEBIG in Europe; build marketing, reimbursement and selling initiatives for the ... $4.95 - PR Newswire - ECNext … Signs Definitive Agreement to Sell PhosLo(R) to Fresenius Medical... - Oct 12, 2006 Nabi Biopharmaceuticals Signs Definitive Agreement to Sell PhosLo(R) to Fresenius Medical Care. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Nabi sues Roxane over PhosLo Gelcap patent.(Nabi Biopharmaceuticals … - Oct 3, 2005 Nabi Biopharmaceuticals says that it has filed a law suit against Roxane Laboratories for infringement of its PhosLo (calcium acetate) gelcap patent. ... $4.95 - Pharma Marketletter - ECNext Fresenius completes buy of Nabi's PhosLo.(Fresenius Medical Care AG)(... - Nov 27, 2006 Germany's Fresenius Medical Care has completed the acquisition of the worldwide phosphate binder business (PhosLo) of Florida, USA-headquartered drugmaker ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Nabi Biopharmaceuticals Announces Fourth Quarter and Full-Year 2006 … - Mar 12, 2007 Revenues for both years excluded sales of PhosLo(R) (calcium acetate) which are ... 2006 Milestones achieved PhosLo(R) (calcium acetate) - Completed sale of ... Free with registration - PR Newswire - AccessMyLibrary.com Q1 2005 Nabi Biopharmaceuticals Earnings Conference Call - Final. - Apr 20, 2005 ...the possibility that we may not realize the value of our acquisition of PhosLo; the company's ability to raise additional capital on acceptable terms; ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Nabi posts $75.6M loss - Feb 24, 2006 Nabi said PhosLo sales were down because it withdrew the tablet form of the ... PhosLo sales were $13.9 million in 2005, down from $37.6 million in 2004. ... South Florida Business Journal New anti-smoking drug may rival Nabi vaccine. - May 12, 2006 Nolan noted that he has done consulting work for Boca Raton-based Nabi, which sells PhosLo, Renagel's biggest competitor. ... Free with registration - Palm Beach Post - AccessMyLibrary.com Nabi Biopharmaceuticals to Present at the CE Unterberg, Towbin … - Oct 17, 2005 We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol ... $4.95 - PR Newswire - ECNext Nabi Biopharmaceuticals Announces Full Year And Fourth Quarter 2005 … - Feb 23, 2006 This resulted in lower total wholesaler inventory levels of PhosLo. In reporting full year PhosLo sales of $13.9 million, the company noted that as part of ... Free with registration - PR Newswire - AccessMyLibrary.com DAX: Düsteres Ifo-Wirtschaftsklima, fröhliche Börsianer - Dec 18, 2008 Die WestLB berichtet, dass die US-Verkäufe der Fresenius Marke PhosLo signifikant unter ein Nachahmerprodukt leiden. Die Bank hält aber an ihrer Empfehlung ... BörseGo.de Ð’ СШÐ? у препарата PhosLo может быть зарегиÑ?трировано еще одно … - Jan 29, 2007 Ð?емецкаÑ? компаниÑ? Fresenius Medical Care подала в FDA заÑ?вление на региÑ?трацию еще одного показаниÑ? длÑ? применениÑ? препарата PhosLo: у пациентов Ñ? ... ФармацевтичеÑ?кий веÑ?тник Vaccine Development; Biopharma company submits marketing … - Jan 17, 2005 Furthermore, Nabi Biopharmaceuticals' acquisition of PhosLo (Calcium Acetate) for the ... Combined, StaphVAX and PhosLo will favorably position Nabi ... Pay-Per-View - AIDS Vaccine Week - Factiva, from Dow Jones Large Proportion of Patients on Renagel(R) Receive Calcium … - Nov 21, 2005 To date and in line with the K/DOQI guidelines, PhosLo effectively controls phosphate in kidney ... PhosLo is administered orally, and when given with food, ... $4.95 - PR Newswire - ECNext Business & Finance; Biopharmaceutical company reports second quarter ... - Aug 16, 2005 Management also noted that total prescriptions for PhosLo (calcium acetate) ... After considering all of these factors, patient utilization of PhosLo ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Nabi Biopharmaceuticals Reports Second Quarter 2005 … - Jul 19, 2005 Management also noted that total prescriptions for PhosLo(R) (calcium acetate) ... After considering all of these factors, patient utilization of PhosLo ... Pay-Per-View - PR Newswire - HighBeam Research Nabi Biopharmaceuticals Updates Its 2005 Revenue Guidance. - Apr 5, 2005 As wholesaler inventories of PhosLo tablets were reduced in the first quarter, ... In line with previous guidance, first quarter PhosLo revenues were based ... $4.95 - PR Newswire - ECNext Fresenius Medical Care "buy" - Oct 22, 2007 Die Produktumsätze würden von der PhosLo-Ãœbernahme profitieren und bei 604,4 Mio. USD erwartet, was einem Plus von 13,9% entsprechen würde. ... AktienCheck Press Release: Nabi Biopharmaceuticals Reports Second Quarter 2006 … - Jul 26, 2006 During the second quarter of 2006, PhosLo revenues were $9.6 million, ... During the month of May 2006, the number of PhosLo prescriptions reached an ... Pay-Per-View - PR Newswire - HighBeam Research … which Demonstrate Superior Serum Phosphorus Control with PhosLo(R)... - Jul 18, 2006 The Reference Member State, which reviewed our application for PhosLo, has already recommended its approval to the five other member states selected, ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: Nabi Biopharmaceuticals Updates Its 2005 Revenue … - Apr 5, 2005 As wholesaler inventories of PhosLo tablets were reduced in the first quarter, ... In line with previous guidance, first quarter PhosLo revenues were based ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Nabi Biopharmaceuticals Sends Letter to Shareholders. ... - Oct 16, 2006 The sale of PhosLo to Fresenius, a company we believe provides a strong ... The sale of PhosLo is the right business decision at the right time and ... Pay-Per-View - PR Newswire - HighBeam Research Nabi Biopharmaceuticals Business Update Call - Part 1. - Oct 1, 2006 The sale of PhosLo has been underway for several months. ... PhosLo is positioned to be a core part of their growing prescription product portfolio in the ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Nabi Biopharmaceuticals Sends Letter to Shareholders. - Oct 16, 2006 The sale of PhosLo to Fresenius, a company we believe provides a strong ... The sale of PhosLo is the right business decision at the right time and ... $4.95 - PR Newswire - ECNext Fresenius Medical Care AG & Co acquires Nabi Biopharm-Phosphate … - Nov 14, 2006 PhosLo is a calcium…second quarter. ##/##/#### Nabi Biopharmaceuticals Fresenius AG; ... Nabi Biopharmaceuticals KEDRION S.p.A…t to Sell PhosLo to Fresenius ... Pay-Per-View - deals - Alacra Store Article: Nabi, Fresenius sign agreement to advance ATG-Fresenius S in... - Apr 17, 2006 Article: Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to ... ... PhosLo is a calcium ... dialysis-related drugs. Fresenius is the world's largest ... Pay-Per-View - Transplant News - HighBeam Research Nabi tells grumbling shareholders two new drugs will be winners. - May 14, 2005 PhosLo -- Nabi's treatment for a condition that causes heart failure in kidney-dialysis ... McLain made a pitch for investors to sit tight, tying PhosLo and ... Free with registration - Palm Beach Post - AccessMyLibrary.com Week in review South Florida Business Journal - Oct 20, 2006 The PhosLo drug treats high phosphate levels in people with kidney failure. During the second quarter, PhosLo revenue hit $9.6 million, up from $3.2 million ... Bizjournals.com EDITED BRIEF - Apr 30, 2008 PhosLo or therapy business. b. Renal products continued to grow at 9% YoverY. c. PhosLo growth was 65% vs. 1Q07, reflects continued increase in pricing ... $54.00 - Thomson StreetEvents - Alacra Store Fresenius Medical Q3 opg beats forecasts, buoyed by North American … - Oct 31, 2007 Sales of Phoslo, which abates excess amounts of phosphate in dialysis patients' blood, jumped 79 pct, meeting the company's expectations, Fresenius Medical ... Forbes Drug sale aims to shore up company: CEO moves to calm shareholder … - Oct 13, 2006 Before financial markets opened, Nabi announced plans to sell its PhosLo drug, ... "Although the PhosLo transaction was initiated well before our recent ... Pay-Per-View - South Florida Sun - Sentinel - HighBeam Research Press Release: Nabi Biopharmaceuticals Updates European … - Dec 19, 2005 PhosLo is a prescription phosphate binder indicated for the control of ... Future clinical infrastructure and marketing support for PhosLo and HEBIG can be ... Pay-Per-View - PR Newswire - HighBeam Research Nabi Biopharmaceuticals Files for European Regulatory Approval for … - Sep 17, 2007 Furthermore, Nabi Biopharmaceuticals' acquisition of PhosLo(R) (Calcium Acetate) for the ... Combined, StaphVAX and PhosLo will favorably position Nabi ... newratings.com Generic drug firm boss charged with ID fraud - Oct 2, 2006 Lyne Laboratories had sensitive information about PhosLo because it manufactured the drug as a subcontractor for Nabi until two years ago. ... In-PharmaTechnologist.com The Bellwether Report is very excited about the future of Nabi … - Feb 27, 2006 The company markets three products: PhosLo for treatment of hyperphosphatemia in ... This resulted in lower total wholesaler inventory levels of PhosLo. ... $4.95 - M2 Presswire - ECNext Nabi sues Ohio company over dialysis drug. - Sep 28, 2005 PhosLo gel caps are a treatment for reducing dangerously high phosphate levels in the ... Nabi holds patents on PhosLo gel caps that were assigned to it by ... Free with registration - Palm Beach Post - AccessMyLibrary.com California Man Charged With Using Stolen Identity in Effort to Obtain... - Sep 28, 2006 It is alleged that in an effort to obtain proprietary information about PhosLo, in June 2005, NATHAN fraudulently used the identity of a senior Nabi ... RedOrbit Merger and Acquisition Scenario - Oct 27, 2007 PhosLo (Calcium Acetate); Fresenius Blood Temperature Monitors; NOVO GS Series ... PhosLo (Calcium Acetate). Urology. Urological Disorders. Kidney (Renal) ... $250.00 - Revere Reports - Revere DAX am Mittag: Leicht positive Stimmung, Henkel gesucht, Continental ... - Nov 21, 2006 Daneben verlieren Anteilsscheine von FMC trotz der Veröffentlichung positiver Ergebnisse der CARE-2-Studie mit PhosLo 0,4 Prozent. ... optionsscheinecheck.de NABI, HEDGE FUND REACH DEAL ON DIRECTORS, CHAIRMAN - Nov 14, 2006 Last month, the company sold its largest revenue generator, PhosLo, ... PhosLo is a treatment for reducing dangerously high phosphate levels in the blood. ... Pay-Per-View - Palm Beach Post - NewsBank INVESTORS AWAIT SIGNALS FROM NABI - Jul 8, 2006 The funds' executives noted that Nabi missed a milestone last week, when the company failed to gain European approval for PhosLo, a kidney drug approved for ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver Loislaw Federal District Court Opinions - NABI BIOPHARMACEUTICALS … - Mar 21, 2007 Nabi is the innovator of a product called PhosLo, a prescription drug used to treat Page 2 ... Nabi holds three patents for PhosLo: Patent No. ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Fresenius Medical Care Confirms Outlook for 2008; Reports Strong … - Jul 30, 2008 This performance was led by strong sales among the whole product portfolio including the phosphate binding drug PhosLo(R). International revenue was $950 ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: California Man Charged with Using Stolen Identity in … - Sep 28, 2006 It is alleged that in an effort to obtain proprietary information about PhosLo, in June 2005, NATHAN fraudulently used the identity of a senior Nabi ... Pay-Per-View - PR Newswire - HighBeam Research calcium acetate Nabi provides update on development.(Brief Article) - Mar 28, 2005 A filing for approval of PhosLo in the treatment of hyperphosphatemia in chronic ... Results from the CARE 2 study of PhosLo, comparing the efficacy and ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Press Release: Nabi Biopharmaceuticals Announces First Quarter 2006 … - Apr 26, 2006 Gains in Product Revenues and Margins Led by PhosLo - - Significant Progress Made ... The gain in PhosLo revenues was driven by a continued increase in new ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Jan 20, 2007 PhosLo (Calcium Acetate); Fresenius Blood Temperature Monitors; NOVO GS Series ... PhosLo (Calcium Acetate). Urology. Urological Disorders. Kidney (Renal) ... $250.00 - Revere Reports - Revere Nabi Biopharmaceuticals Announces Results of StaphVAX(R) … - Nov 1, 2005 We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol ... RedOrbit Merger and Acquisition Scenario - Aug 4, 2007 PhosLo (Calcium Acetate); Fresenius Blood Temperature Monitors; NOVO GS Series ... PhosLo (Calcium Acetate). Healthcare Services. Health Plans. $250.00 - Revere Reports - Revere Article: Nabi Biopharmaceuticals sues Roxanne Labs over kidney... - Oct 31, 2005 PhosLO gelcaps are a treatment for reducing dangerously high phosphate levels in the ... Nabi holds patents on PhosLo gelcaps that were assigned to it by ... Pay-Per-View - Transplant News - HighBeam Research Nabi Biopharmaceuticals Launches New Study to Evaluate StaphVAX(R)' … - Sep 20, 2005 We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol ... RedOrbit Nabi Biopharmaceuticals' Mark L. Smith Resigns as Company's CFO, … - Mar 1, 2006 We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol ... prnewswire.com Merger and Acquisition Scenario - Jun 7, 2008 PhosLo (Calcium Acetate); Voluven (Synthetic Starch); Fresenius Blood Temperature ... PhosLo (Calcium Acetate). Surgery. General. Complications. Hemorrhage ... $250.00 - Revere Reports - Revere Finance; Biopharmaceutical company reports year-end and fourth... - Mar 14, 2005 In addition, the experience and relationships we are building in marketing PhosLo in the United States will be invaluable as we build our commercial ... Pay-Per-View - Hematology Week - Factiva, from Dow Jones Nabi Biopharmaceuticals Announces Successful Results from StaphVAX( … - Oct 12, 2005 We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol ... $4.95 - PR Newswire - ECNext Genzyme 3rd-Quarter Profit Drops 86% on Acquisitions - Oct 12, 2006 Earlier today, Fresenius Medical Care AG, the world's biggest provider of kidney dialysis, agreed to buy Nabi Biopharmaceuticals Inc.'s Phoslo treatment, ... Bloomberg Press Release: Roxane Laboratories, Inc. Updated Launch of Calcium … - Oct 22, 2008 Annual sales of PhosLo(R) (calcium acetate) capsules are approximately $84.8 million(1). Full prescribing information for calcium acetate capsules, ... Pay-Per-View - PR Newswire - HighBeam Research Finance; Biopharmaceutical company reports year-end and fourth... - Mar 18, 2005 In addition, the experience and relationships we are building in marketing PhosLo in the United States will be invaluable as we build our commercial ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Factiva Search - Aug 3, 2005 Nabi Biopharmaceuticals' new PhosLo Share Program expands access to broader population of ... Nabi Biopharmaceuticals has launched the PhosLo Share Program, ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Nabi Biopharmaceuticals sues Roxanne Labs over kidney dialysis drug. - Oct 31, 2005 PhosLO gelcaps are a treatment for reducing dangerously high phosphate levels in the ... Nabi holds patents on PhosLo gelcaps that were assigned to it by ... $9.94 - Transplant News - Alacra Store Press Release: Nabi Biopharmaceuticals Reports Third Quarter 2005 … - Oct 19, 2005 PhosLo(R) Demand Remains Strong - - Company on Track to Announce ... Reported PhosLo revenues totaled $8.1 million and correlate to patient usage during the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Nabi Biopharmaceuticals to Present at the Bear Stearns... - May 6, 2005 We have three products on the market today (PhosLo(R), Nabi-HB(R), ... Nabi Biopharmaceuticals currently markets PhosLo in the United States for this ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Nabi Biopharmaceuticals Reports Third Quarter 2006 … - Oct 25, 2006 ..."The agreement to sell PhosLo to Fresenius is expected to provide us with a ... The sale of PhosLo will allow us to make further reductions in selling, ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Nov 18, 2006 PhosLo (Calcium Acetate); Renaissance Health Care; Fresenius Blood Temperature Monitors ... PhosLo (Calcium Acetate). Urology. Urological Disorders. $250.00 - Revere Reports - Revere FLORIDA DRUG FIRM NABI RELOCATES TO ROCKVILLE - Dec 5, 2007 The remaining, Rockville-based Nabi has potential for up to $75 million in revenue over 10 years from royalties on the sales of PhosLo, a product it ... Pay-Per-View - The Sun - ProQuest Archiver Merger and Acquisition Scenario - May 3, 2008 PhosLo (Calcium Acetate); Voluven (Synthetic Starch); Renaissance Health Care; Fresenius Blood ... PhosLo (Calcium Acetate). Surgery. General. Complications. $250.00 - Revere Reports - Revere Fresenius Medical Care Holdings, Inc. v. Roxane Laboratories, Inc.,... - Mar 21, 2007 Before Nabi acquired assets relating to the sale of PhosLo(r) calcium acetate products, Braintree owned the original patent for the PhosLo(r) gelcap. ... $2.95 - U.S. District Court, Southern District... - VersusLaw BUSINESS BRIEFING - Sep 28, 2005 ...a lawsuit against privately held Roxane Laboratories Inc., alleging infringement on a patent for gel-cap PhosLo, a Nabi product for kidney disease. ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver Press Release: Braintree Laboratories, Inc. In-Licenses Global Rights... - Mar 9, 2006 ...(1) PhosLo is a registered trademark of Nabi Biopharmaceuticals, Boca Raton, FL. ... Article: Nabi Biopharmaceuticals Acquires Worldwide Rights To PhosLo(R) ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Nabi Biopharmaceuticals to Present at the Thomas … - Sep 2, 2005 Nabi Biopharmaceuticals currently markets PhosLo in the United States for this indication . ... Article: Nabi Biopharmaceuticals Files PhosLo(R) Common ... ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Halflytely(R) Now Available With Flavor Packs. - PR … - Jun 30, 2005 Article: Nabi Biopharmaceuticals Acquires Worldwide Rights To PhosLo(R) ... ... StaphVAX, announcing our agreement to acquire PhosLo from Braintree ... Pay-Per-View - PR Newswire - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |